Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 3:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 802 matching trials from the live ClinicalTrials.gov search.
Conditions
Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Collecting Duct Carcinoma, Kidney Medullary Carcinoma, Metastatic Malignant Neoplasm in the Bone, Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Unclassified Renal Cell Carcinoma
Interventions
Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Radium Ra 223 Dichloride
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
47
States / cities
Birmingham, Alabama • La Jolla, California • Sacramento, California + 37 more
Conditions
Renal Cell Carcinoma
Interventions
Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Kidney Cancer, Melanoma (Skin), Metastatic Cancer, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cryosurgery, radiation therapy
Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 3 more
Conditions
Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
celecoxib, recombinant interferon alfa-2b, polymerase chain reaction, laboratory biomarker analysis, reverse transcriptase-polymerase chain reaction, immunologic technique, immunohistochemistry staining method, flow cytometry
Drug · Biological · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Metastatic Clear Cell Renal Cell Carcinoma
Interventions
LY2510924, Sunitinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
21
States / cities
Scottsdale, Arizona • Norwich, Connecticut • Newark, Delaware + 18 more
Conditions
Kidney Cancer
Interventions
alvocidib
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
101
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 64 more
Conditions
Metastatic Clear Cell Renal Cell Carcinoma
Interventions
IL-2, Stereotactic Ablative Body Radiation Therapy
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Esophageal Cancer, Gastric Cancer, Melanoma, Renal Cell Carcinoma, Pancreatic Cancer, Cervical Cancer, Triple Negative Breast Cancer, Advanced Cancer, Metastatic Cancer
Interventions
Alomfilimab, Atezolizumab
Drug
Lead sponsor
Kymab Limited
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
6
States / cities
Duarte, California • New Haven, Connecticut • Orlando, Florida + 3 more
Conditions
Kidney Neoplasms
Interventions
SU-011,248
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
15
States / cities
Los Angeles, California • Mission Hills, California • Monterey Park, California + 9 more
Conditions
Genitourinary Cancer, Kidney Cancer
Interventions
Sunitinib, Questionnaire
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
5
States / cities
Stanford, California • Chapel Hill, North Carolina • Cleveland, Ohio + 2 more
Conditions
Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer
Interventions
Gemcitabine hydrochloride, Paclitaxel, Doxorubicin hydrochloride, Pegfilgrastim
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
2
States / cities
Springfield, Missouri • Houston, Texas
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Prostate Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Sarcoma, Metastatic Thyroid Gland Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Cryosurgery, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
Procedure · Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
vorinostat, bevacizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
3
States / cities
Baltimore, Maryland • Salisbury, Maryland • Madison, Wisconsin
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
Nivolumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Carcinoma, Renal Cell
Interventions
Pazopanib, Sunitinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
96
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 82 more
Conditions
Stage IV Melanoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, Recurrent Melanoma
Interventions
flt3 ligand, gp100 antigen, MART-1 antigen, Montanide ISA-51, tyrosinase peptide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Timeline
1998 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Renal Cell Carcinoma
Interventions
Sorafenib, temsirolimus (Torisel)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
26
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 19 more
Conditions
Renal Cell Cancer, Kidney Cancer
Interventions
Sunitinib, Temsirolimus
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Houston, Texas
Conditions
Carcinoma, Renal Cell
Interventions
Sunitinib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Kidney Cancer, Melanoma (Skin)
Interventions
recombinant interleukin-7, gene expression analysis, polymerase chain reaction, protein expression analysis, flow cytometry, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, pharmacological study
Biological · Genetic · Other
Lead sponsor
Cytheris SA
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Recurrent Melanoma, Recurrent Pancreatic Cancer, Recurrent Renal Cell Cancer, Stage III Pancreatic Cancer, Stage III Renal Cell Cancer, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
siRNA-transfected peripheral blood mononuclear cells APN401, laboratory biomarker analysis
Biological · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Carcinoma, Renal Cell
Interventions
Sunitinib Malate Continuous Daily Dosing, Sunitinib Malate Schedule 4/2
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
156
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 114 more
Conditions
Neoplasm Metastasis, Brain Neoplasms
Interventions
Motexafin gadolinium
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Phoenix, Arizona • Aurora, Colorado • Cleveland, Ohio + 6 more
Conditions
Renal Cell Carcinoma
Interventions
Everolimus, GDC-0980
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Boston, Massachusetts + 5 more